Chicca, Andrea; Batora, Daniel; Ullmer, Christoph; Caruso, Antonello; Fingerle, Jürgen; Hartung, Thomas; Degen, Roland; Müller, Matthias; Grether, Uwe; Pacher, Pal; Gertsch, Jürg (29 April 2024). A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies. (bioRxiv). Cold Spring Harbor Laboratory 10.1101/2024.04.26.591311
|
Text
2024.04.26.591311v1.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and for target validation in vivo, optimal pharmacological tool compounds are essential. Despite the sizable progress in the generation of potent and selective CB2R ligands, pharmacokinetic parameters are often neglected for in vivo studies. Here, we report the generation and characterization of a tetra-substituted pyrazole CB2R full agonist named RNB-61 with high potency (K i 0.13-1.81 nM, depending on species) and a peripherally restricted action due to P-glycoprotein mediated efflux from the brain. 3H and 14C labelled RNB-61 showed apparent K d values < 4 nM towards human CB2R in both cell and tissue experiments. The >6000-fold selectivity over CB1 receptors and negligible off-targets in vitro, combined with high oral bioavailability and suitable systemic pharmacokinetic (PK) properties, prompted the assessment of RNB-61 in a mouse ischemia-reperfusion model of acute kidney injury (AKI) and in a rat model of chronic kidney injury/inflammation and fibrosis (CKI) induced by unilateral ureteral obstruction. RNB-61 exerted dose-dependent nephroprotective and/or antifibrotic effects in the AKI/CKI models. Thus, RNB-61 is an optimal CB2R tool compound for preclinical in vivo studies with superior biophysical and PK properties over generally used CB2R ligands.
Item Type: |
Working Paper |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine |
Graduate School: |
Graduate School for Cellular and Biomedical Sciences (GCB) |
UniBE Contributor: |
Chicca, Andrea, Gertsch, Jürg |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
2692-8205 |
Series: |
bioRxiv |
Publisher: |
Cold Spring Harbor Laboratory |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
28 Jun 2024 14:53 |
Last Modified: |
29 Jun 2024 09:15 |
Publisher DOI: |
10.1101/2024.04.26.591311 |
PubMed ID: |
38903103 |
BORIS DOI: |
10.48350/198200 |
URI: |
https://boris.unibe.ch/id/eprint/198200 |
Actions (login required)
 |
Edit item |